Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.

MLA

Banales, Jesus M., et al. “Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.” Hepatology (Baltimore, Md.), vol. 70, no. 2, Aug. 2019, pp. 547–62. EBSCOhost, https://doi.org/10.1002/hep.30319.

APA

Banales, J. M., Iñarrairaegui, M., Arbelaiz, A., Milkiewicz, P., Muntané, J., Muñoz-Bellvis, L., La Casta, A., Gonzalez, L. M., Arretxe, E., Alonso, C., Martínez-Arranz, I., Lapitz, A., Santos-Laso, A., Avila, M. A., Martínez-Chantar, M. L., Bujanda, L., Marin, J. J. G., Sangro, B., & Macias, R. I. R. (2019). Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology (Baltimore, Md.), 70(2), 547–562. https://doi.org/10.1002/hep.30319

Chicago

Banales, Jesus M, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz-Bellvis, Adelaida La Casta, et al. 2019. “Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.” Hepatology (Baltimore, Md.) 70 (2): 547–62. doi:10.1002/hep.30319.